

**Pure Protein Presents Disease Epitope Discovery Research and Introduces
New 120-allele HLA Class I Single Antigen Assay at the 2012 Annual Meeting of
the American Society of Histocompatibility and Immunogenetics (ASHI)**

OKLAHOMA CITY, OK and AUSTIN, TX – October 1, 2012 – Pure Protein, L.L.C. (PURE) has announced the company will deliver twelve oral and print poster presentations at the Annual Meeting of the American Society of Histocompatibility and Immunogenetics (ASHI) in Puerto Rico, October 8th through October 12th. The presentations will detail the research and achievements completed in the PURE labs during the last year.

Chief Scientific Officer William Hildebrand, Ph.D., Director of Research Rico Buchli, Ph.D., and a team of PURE corporate executives, research, and commercial manufacturing staff will deliver the presentations that include the following topics:

- Factors that influence consistency in HLA single antigen assays – a study discussing future standardization strategies
- Forced degradation studies – soluble HLA stress testing compromising the integrity of HLA proteins on single antigen beads
- The making of anti-HLA antibody removal matrices – a performance study
- Soluble HLA – a new generation of single antigen assays
- Profiling purified HLA-DR specific antibodies (oral)
- West Nile Virus peptide presentation by HLA-A versus HLA-B.
- The influence of anti-HLA antibody concentration and isotypes on SAB MFI (oral)

In addition, Dr Hildebrand will be chairing presentation sessions at 2pm on Tuesday, October 10th and Thursday, October 11th.

Dr. Hildebrand is a renowned scientist and founder of Pure Protein. He has authored more than 120 publications and holds 77 patents in fields related to the discovery and use of the HLA protein technology developed in his lab. After the founding of Pure Protein in 1999, Dr. Hildebrand launched two additional subsidiary companies, Pure Transplant Solutions and Pure Vaccine Solutions in 2003. The three companies were formed on the principle that a best-in-class source of native soluble HLA proteins would contribute to setting industry standards for cross-reactive antibody screening; and to modulating and understanding autoimmune, transplant, pathogen, and vaccine derived immune responses.

Dr. Hildebrand said, “ASHI is a key meeting for our team. Pure Protein has accomplished significant work in the last year applying our soluble HLA technology to the areas of perfecting single-antigen binding assays and epitope discovery for several major diseases. We have learned some exciting things and find the ASHI contingent to be an important confluence of the histocompatibility and immunogenetics thought leaders with which to share this information.”

About Pure Protein

Pure Protein is an HLA Center of Excellence – developing immunology tools for therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Protein was formed in 1999 to commercialize research developed at the University of Oklahoma Health Sciences Center. Pure Transplant Solutions, L.L.C., a subsidiary of Pure Protein, is using HLA protein to develop diagnostics, devices, and therapeutics which will eliminate rejection in organ transplants. Pure Vaccine Solutions, another subsidiary of Pure Protein, is using HLA protein to discover valuable new vaccine targets, improve existing vaccines, and design clinical trials for vaccine candidates. Pure Protein and its subsidiaries are funded and managed by innovation solutions company Emergent Technologies, Inc. For more information, please visit the website www.pureproteinllc.com.

About Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages, develops and partners to turn game-changing scientific discoveries into market-driven products. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. The company applies its experience and expertise to provide investors, entrepreneurs, communities and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit the Emergent website www.emergentechnologies.com.

###

Media Contact:

Sandra G. Oak
Nsign Public Relations
321-591-1508
soak@nsightpr.com